Medication info
Zepogajeong 10 mg (Dapagliflozin Propanediol Hydrate)

Zepogajeong 10 mg (Dapagliflozin Propanediol Hydrate)

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Propanediol Hydrate›12.3mg / 1 tablet
Manufacturer / importer
Jeil Pharmaceutical Co., Ltd.
Appearance
Yellow, biconvex, diamond-shaped film-coated tablets
Packaging
28 tablets (14 tablets/PTP × 2)
Approval status
Active

MFDS item code 202201082 · Approved 2022.03.16 · Insurance code 645406280

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus; treatment of chronic heart failure and chronic kidney disease
Who takes it
Adults · Children
Adult dose
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this drug is 10 mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this drug is used in combination with insulin or insulin secretagogues such as sulfonylureas, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients with no prior experience of diabetes drug therapy, when administered in combination with metformin, the recommended initial dose of this drug is 5 mg once daily or 10 mg once daily. Chronic heart failure and chronic kidney disease The recommended dose of this drug is 10 mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Administration of this drug is not recommended for the purpose of improving glycemic control. - eGFR less than 25 mL/min/1.73m2: Initiation of this drug is not recommended in patients with chronic heart failure and chronic kidney disease. - Patients on dialysis: Do not administer this drug. Hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, a starting dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Older adults (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This drug may be taken orally once daily at any time of day, with or without food. The tablet should be swallowed whole.
Child dose
The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.

Ingredients

Manufacturer
Jeil Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus; treatment of chronic heart failure and chronic kidney disease

  • Type 2 diabetes
  • blood sugar regulation disorders
  • cardiovascular disease
  • risk factors for cardiovascular disease
  • chronic heart failure
  • heart failure
  • chronic kidney disease
  • reduced glomerular filtration rate
  • end-stage kidney disease
View approved original text

This medication is used in conjunction with dietary and exercise regimens to help control blood sugar in patients with type 2 diabetes. It also helps reduce the occurrence of cardiovascular events in patients at risk for cardiovascular disease. In patients with chronic heart failure, it is administered along with other heart failure therapies to reduce the risk of death and hospitalization due to cardiovascular disease. Additionally, it contributes to mitigating the decline in kidney function and the risk of cardiovascular disease and kidney-related mortality in patients with chronic kidney disease. This medication is effectively used not only for blood sugar control but also for preventing complications of heart failure and kidney disease.

How to take

Adult dose

Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this drug is 10 mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this drug is used in combination with insulin or insulin secretagogues such as sulfonylureas, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients with no prior experience of diabetes drug therapy, when administered in combination with metformin, the recommended initial dose of this drug is 5 mg once daily or 10 mg once daily. Chronic heart failure and chronic kidney disease The recommended dose of this drug is 10 mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Administration of this drug is not recommended for the purpose of improving glycemic control. - eGFR less than 25 mL/min/1.73m2: Initiation of this drug is not recommended in patients with chronic heart failure and chronic kidney disease. - Patients on dialysis: Do not administer this drug. Hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, a starting dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Older adults (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This drug may be taken orally once daily at any time of day, with or without food. The tablet should be swallowed whole.

Child dose

The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.

Precautions

This medication should not be administered to certain patients. It should not be used in patients who are allergic to the active ingredients or excipients, patients with type 1 diabetes or diabetic ketoacidosis, those with genetic lactose intolerance issues, and patients who are undergoing dialysis. It should be used cautiously in patients with reduced fluid volume or kidney dysfunction, and fluid status and kidney function should be assessed before administration. After administration, symptoms of hypotension and kidney function should be monitored periodically. This medication is not recommended for patients with severely reduced kidney function. In clinical trials and post-marketing studies, the most common side effect has been genital infections, which may occur more frequently in women or patients with a history of infections. Hypoglycemia may occur primarily when used in combination with insulin or sulfonylureas; thus, dosage adjustment of insulin or secretagogues may be necessary to reduce the risk of hypoglycemia. Symptoms of dehydration or hypotension due to reduced fluid volume may occur; immediate consultation with healthcare personnel is required if such symptoms arise. Diabetic ketoacidosis can occur even when blood sugar levels are not high; symptoms such as nausea, vomiting, abdominal pain, and difficulty breathing require immediate investigation and treatment. There is an increased risk of urinary tract infections and pyelonephritis; rapid treatment is necessary if signs of infection occur. There is limited experience using this medication in patients with severely impaired liver function, so caution is required. It is recommended that women who are pregnant or breastfeeding do not use this medication, and administration should be discontinued if pregnancy is confirmed. Elderly patients should have careful monitoring of kidney function and fluid status. During the course of this medication, glucose may be detected in urine tests, which should be taken into account when evaluating blood sugar control. There is no specific antidote for overdose; appropriate treatment should be administered according to symptoms. Finally, while this medication does not significantly impact the ability to drive or operate machinery, caution is needed due to the risk of hypoglycemia when used in combination with insulin and others.

Side effects

Vulvovaginal candidiasis, balanitis and related genital infections, urinary tract infections, fungal infections, perineal necrosis, hypoglycemia, decreased fluid volume, polydipsia, diabetic ketoacidosis, dizziness, constipation, dry mouth, low back pain, dysuria, polyuria, nocturia, interstitial nephritis, vulvar itching, genital itching, increased hematocrit, initial treatment decrease in renal creatinine clearance, dyslipidemia, initial treatment increase in serum creatinine, elevated blood urea, weight loss, urosepticemia, pyelonephritis, acute kidney injury, renal dysfunction, rash, angioedema, gastroesophageal reflux disease, upper abdominal pain, diverticulosis, intestinal perforation, acute pancreatitis, chronic pancreatitis, hyperglycemia, paresthesia, cerebral infarction, nerve compression, asthenia, pain, keratitis, chronic obstructive pulmonary disease, hemoptysis, intracerebral hemorrhage, peripheral artery occlusion, angina, myocardial infarction, depression, suicide attempt, gastric adenocarcinoma, anaphylactic reaction, acute pyelonephritis, chest pain, chronic gastritis, frequent bowel movements, gastroenteritis, colorectal polyps, epigastric discomfort, functional dyspepsia, erosive gastritis, gum disorders, gum pain, hemorrhoids, hiatal hernia, irritable bowel syndrome, melena, urgency, diabetic nephropathy, overactive bladder, microalbuminuria, stress urinary incontinence, urinary hesitancy, urinary stones, abnormal urination, increased serum lactate, lymphocytopenia, vitamin D deficiency, increased appetite, taste disturbance, drowsiness, tension headache, carpal tunnel syndrome, diabetic neuropathy, unconsciousness, neuralgia, peripheral neuropathy, sleep disorders, syncope, tremors, bronchitis, shingles, sinusitis, tonsillitis, styes, joint abscess, laryngitis, otitis media, pelvic inflammatory disease, pericoronitis, pneumonia, pulmonary tuberculosis, rhinitis, onychomycosis, herpes simplex, edema, fever, foreign body sensation, facial edema, facial pain, warmth, flu-like syndrome, fatigue, chest discomfort, peripheral edema, generalized edema, hunger, breast lump, erectile dysfunction, benign prostatic hyperplasia, breast pain, genital rash, menorrhagia, genital edema, uterine bleeding, vaginal bleeding, vulvar discomfort, menstrual irregularities, hair loss, dermatitis, xerosis, allergic dermatitis, contact dermatitis, diabetic foot ulcer, sweating dysregulation eczema, coin-shaped eczema, eczema, hyperkeratosis, nail pigmentation, skin lesions, urticaria, cold sweat, arthralgia, musculoskeletal pain, limb pain, muscle weakness, myalgia, osteoarthritis, ligament sprain, diabetic retinopathy, cough, dyspnea, orthostatic hypotension, palpitations, insomnia, fatty liver, gallbladder polyps, tinnitus

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is important to maintain storage temperatures between 1 degree and 30 degrees Celsius. Proper storage will ensure that the medication's effectiveness and safety are maintained for an extended period.

Appearance and packaging

Appearance

Yellow, biconvex, diamond-shaped film-coated tablets

Package unit

28 tablets (14 tablets/PTP × 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.